Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report.

Aris M, Bravo AI, Pampena MB, Blanco PA, Carri I, Koile D, Yankilevich P, Levy EM, Barrio MM, Mordoh J.

Front Immunol. 2018 May 3;9:955. doi: 10.3389/fimmu.2018.00955. eCollection 2018.

2.

Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study.

Mordoh J, Pampena MB, Aris M, Blanco PA, Lombardo M, von Euw EM, Mac Keon S, Yépez Crow M, Bravo AI, O'Connor JM, Orlando AG, Ramello F, Levy EM, Barrio MM.

Front Immunol. 2017 May 31;8:625. doi: 10.3389/fimmu.2017.00625. eCollection 2017.

3.

Metallothionein 1G promotes the differentiation of HT-29 human colorectal cancer cells.

Arriaga JM, Bravo AI, Mordoh J, Bianchini M.

Oncol Rep. 2017 May;37(5):2633-2651. doi: 10.3892/or.2017.5547. Epub 2017 Apr 3.

4.

Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARC.

Güttlein LN, Benedetti LG, Fresno C, Spallanzani RG, Mansilla SF, Rotondaro C, Raffo Iraolagoitia XL, Salvatierra E, Bravo AI, Fernández EA, Gottifredi V, Zwirner NW, Llera AS, Podhajcer OL.

Mol Cancer Res. 2017 Mar;15(3):304-316. doi: 10.1158/1541-7786.MCR-16-0243-T. Epub 2016 Dec 28.

5.

Glycosylation-dependent binding of galectin-8 to activated leukocyte cell adhesion molecule (ALCAM/CD166) promotes its surface segregation on breast cancer cells.

Fernández MM, Ferragut F, Cárdenas Delgado VM, Bracalente C, Bravo AI, Cagnoni AJ, Nuñez M, Morosi LG, Quinta HR, Espelt MV, Troncoso MF, Wolfenstein-Todel C, Mariño KV, Malchiodi EL, Rabinovich GA, Elola MT.

Biochim Biophys Acta. 2016 Oct;1860(10):2255-68. doi: 10.1016/j.bbagen.2016.04.019. Epub 2016 Apr 26.

PMID:
27130882
6.

Inoculation site from a cutaneous melanoma patient treated with an allogeneic therapeutic vaccine: a case report.

Aris M, Bravo AI, Barrio MM, Mordoh J.

Front Immunol. 2015 Mar 30;6:144. doi: 10.3389/fimmu.2015.00144. eCollection 2015.

7.

Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.

Roberti MP, Juliá EP, Rocca YS, Amat M, Bravo AI, Loza J, Coló F, Loza CM, Fabiano V, Maino M, Podhorzer A, Fainboim L, Barrio MM, Mordoh J, Levy EM.

Eur J Immunol. 2015 May;45(5):1560-9. doi: 10.1002/eji.201445353. Epub 2015 Apr 7.

8.

Atheroprotective remodelling of vascular dermatan sulphate proteoglycans in response to hypercholesterolaemia in a rat model.

Oberkersch R, Maccari F, Bravo AI, Volpi N, Gazzaniga S, Calabrese GC.

Int J Exp Pathol. 2014 Jun;95(3):181-90. doi: 10.1111/iep.12072. Epub 2014 Mar 7.

9.

CD207⁺ cells recruitment to the vaccination site and draining lymph nodes after the administration of DC-Apo/Nec vaccine in mice.

Ruiz MS, Mac Keon S, Campisano S, Bravo AI, Gazzaniga S, Wainstok R.

Vaccine. 2014 Mar 5;32(11):1229-32. doi: 10.1016/j.vaccine.2014.01.025. Epub 2014 Jan 29.

PMID:
24486365
10.

Acquired epidermodysplasia verruciformis in a patient with congenital HIV infection.

Castro-Perez GA, Sorin I, Bravo AI, Mazzuoccolo LD.

Actas Dermosifiliogr. 2013 Oct;104(8):731-3. doi: 10.1016/j.adengl.2012.10.013. No abstract available.

PMID:
24067256
11.

Primary cutaneous mantle cell lymphoma: a case report.

Mazzuoccolo LD, Castro Perez GA, Sorin I, Bravo AI.

Case Rep Dermatol Med. 2013;2013:394596. doi: 10.1155/2013/394596. Epub 2013 May 23.

12.

IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.

Roberti MP, Rocca YS, Amat M, Pampena MB, Loza J, Coló F, Fabiano V, Loza CM, Arriaga JM, Bianchini M, Barrio MM, Bravo AI, Domenichini E, Chacón R, Mordoh J, Levy EM.

Breast Cancer Res Treat. 2012 Dec;136(3):659-71. doi: 10.1007/s10549-012-2287-y. Epub 2012 Oct 14.

PMID:
23065032
13.

A tumor-stroma targeted oncolytic adenovirus replicated in human ovary cancer samples and inhibited growth of disseminated solid tumors in mice.

Lopez MV, Rivera AA, Viale DL, Benedetti L, Cuneo N, Kimball KJ, Wang M, Douglas JT, Zhu ZB, Bravo AI, Gidekel M, Alvarez RD, Curiel DT, Podhajcer OL.

Mol Ther. 2012 Dec;20(12):2222-33. doi: 10.1038/mt.2012.147. Epub 2012 Sep 4.

14.

Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice.

Roberti MP, Arriaga JM, Bianchini M, Quintá HR, Bravo AI, Levy EM, Mordoh J, Barrio MM.

Cancer Biol Ther. 2012 Sep;13(11):1123-40. doi: 10.4161/cbt.21187. Epub 2012 Jul 24.

15.

MART-1- and gp100-expressing and -non-expressing melanoma cells are equally proliferative in tumors and clonogenic in vitro.

Aris M, Zubieta MR, Colombo M, Arriaga JM, Bianchini M, Alperovich M, Bravo AI, Barrio MM, Mordoh J.

J Invest Dermatol. 2012 Feb;132(2):365-74. doi: 10.1038/jid.2011.312. Epub 2011 Oct 13.

16.

Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival.

Arriaga JM, Levy EM, Bravo AI, Bayo SM, Amat M, Aris M, Hannois A, Bruno L, Roberti MP, Loria FS, Pairola A, Huertas E, Mordoh J, Bianchini M.

Hum Pathol. 2012 Feb;43(2):197-208. doi: 10.1016/j.humpath.2011.04.015. Epub 2011 Aug 4.

PMID:
21820154
17.

IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.

Roberti MP, Barrio MM, Bravo AI, Rocca YS, Arriaga JM, Bianchini M, Mordoh J, Levy EM.

Breast Cancer Res Treat. 2011 Nov;130(2):465-75. doi: 10.1007/s10549-011-1360-2. Epub 2011 Feb 10.

PMID:
21308409
18.

Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue.

Mac Keon S, Gazzaniga S, Mallerman J, Bravo AI, Mordoh J, Wainstok R.

Vaccine. 2010 Nov 29;28(51):8162-8. doi: 10.1016/j.vaccine.2010.09.095. Epub 2010 Oct 27.

PMID:
20937314
19.

Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses.

Lopez MV, Viale DL, Cafferata EG, Bravo AI, Carbone C, Gould D, Chernajovsky Y, Podhajcer OL.

PLoS One. 2009;4(4):e5119. doi: 10.1371/journal.pone.0005119. Epub 2008 Apr 8.

20.

Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer.

Levy EM, Bianchini M, Von Euw EM, Barrio MM, Bravo AI, Furman D, Domenichini E, Macagno C, Pinsky V, Zucchini C, Valvassori L, Mordoh J.

Int J Oncol. 2008 Mar;32(3):633-41.

PMID:
18292941
21.

SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth.

Prada F, Benedetti LG, Bravo AI, Alvarez MJ, Carbone C, Podhajcer OL.

J Invest Dermatol. 2007 Nov;127(11):2618-28. Epub 2007 Jul 12.

22.

Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft.

Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A, Mantovani A, Mordoh J, Wainstok R.

J Invest Dermatol. 2007 Aug;127(8):2031-41. Epub 2007 Apr 26.

23.

A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients.

Barrio MM, de Motta PT, Kaplan J, von Euw EM, Bravo AI, Chacón RD, Mordoh J.

J Immunother. 2006 Jul-Aug;29(4):444-54.

PMID:
16799340
24.

Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies.

Zubieta MR, Furman D, Barrio M, Bravo AI, Domenichini E, Mordoh J.

Am J Pathol. 2006 May;168(5):1666-75.

25.

IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis.

Lopez MV, Adris SK, Bravo AI, Chernajovsky Y, Podhajcer OL.

J Immunol. 2005 Nov 1;175(9):5885-94.

26.

Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity.

Alvarez MJ, Prada F, Salvatierra E, Bravo AI, Lutzky VP, Carbone C, Pitossi FJ, Chuluyan HE, Podhajcer OL.

Cancer Res. 2005 Jun 15;65(12):5123-32.

27.

Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.

Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R.

J Immunol. 2003 Dec 1;171(11):5940-7.

28.

Androgen receptors in human melanoma cell lines IIB-MEL-LES and IIB-MEL-IAN and in human melanoma metastases.

Morvillo V, Lüthy IA, Bravo AI, Capurro MI, Portela P, Calandra RS, Mordoh J.

Melanoma Res. 2002 Dec;12(6):529-38.

PMID:
12459642
29.

A new epitope on human melanoma-associated antigen CD63/ME491 expressed by both primary and metastatic melanoma.

Barrio MM, Bravo AI, Portela P, Hersey P, Mordoh J.

Hybridoma. 1998 Aug;17(4):355-64.

PMID:
9790070
30.

The human breast cancer cell line IIB-BR-G has amplified c-myc and c-fos oncogenes in vitro and is spontaneously metastatic in vivo.

Bover L, Barrio M, Bravo AI, Slavutsky I, Larripa I, Bolondi A, Ayala M, Mordoh J.

Cell Mol Biol (Noisy-le-grand). 1998 May;44(3):493-504.

PMID:
9620446
31.

Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells.

Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernajovsky Y, Mordoh J, Podhajcer OL.

Nat Med. 1997 Feb;3(2):171-6.

PMID:
9018235
32.

The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma.

Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL.

J Invest Dermatol. 1997 Feb;108(2):210-4.

33.

Tumor cells engineered to express interleukin-6 exhibit a reduced tumorigenicity depending on the tumor cell model.

Ledda MF, Adris S, Bravo AI, Bover L, Carbone C, Paleolog E, Mordoh J, Chernajovsky Y, Podhajcer OL.

Cell Mol Biol (Noisy-le-grand). 1996 Jul;42(5):769-78.

PMID:
8832108
34.

Atypical androgen receptor in the human melanoma cell line IIB-MEL-J.

Morvillo V, Luthy IA, Bravo AI, Capurro MI, Donaldson M, Quintans C, Calandra RS, Mordoh J.

Pigment Cell Res. 1995 Jun;8(3):135-41.

PMID:
7567789
35.

Biologic, immunocytochemical, and cytogenetic characterization of two new human melanoma cell lines: IIB-MEL-LES and IIB-MEL-IAN.

Kairiyama C, Slavutsky I, Larripa I, Morvillo V, Bravo AI, Bover L, Podhajcer OL, Mordoh J.

Pigment Cell Res. 1995 Jun;8(3):121-31.

PMID:
7567787
36.

Phase I clinical trial in cancer patients of a new monoclonal antibody FC-2.15 reacting with tumor proliferating cells.

Mordoh J, Silva C, Albarellos M, Bravo AI, Kairiyama C.

J Immunother Emphasis Tumor Immunol. 1995 Apr;17(3):151-60.

PMID:
7613641
37.

Expression of cathepsin D in primary and metastatic human melanoma and dysplastic nevi.

Podhajcer OL, Bover L, Bravo AI, Ledda MF, Kairiyama C, Calb I, Guerra L, Capony F, Mordoh J.

J Invest Dermatol. 1995 Mar;104(3):340-4.

38.

Description of a new monoclonal antibody, FC-2.15, reactive with human breast cancer and other human neoplasias.

Mordoh J, Leis S, Bravo AI, Podhajcer OL, Ballare C, Capurro M, Kairiyama C, Bover L.

Int J Biol Markers. 1994 Jul-Sep;9(3):125-34.

PMID:
7829891
39.

[Small cell pulmonary carcinoma, nephrotic syndrome and kidney failure of rapid evolution].

Comolli RR, Zabala JR, Suárez AA, Bravo AI.

Medicina (B Aires). 1994;54(2):153-8. Review. Spanish.

PMID:
7997133
40.

Marker expression and differentiation in human breast cancer.

Ballare C, Bravo AI, Turchi V, Nuti M, Yomha R, Schiaffi J, Mordoh J.

Ann N Y Acad Sci. 1993 Nov 30;698:143-7. No abstract available.

PMID:
8279752
41.

Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor.

Bover L, Barrio M, Slavutsky I, Bravo AI, Quintans C, Bagnăti A, Lema B, Schiaffi J, Yomha R, Mordoh J.

Breast Cancer Res Treat. 1991 Sep;19(1):47-56.

PMID:
1661624
42.

The expression of progesterone receptors coincides with an arrest of DNA synthesis in human breast cancer.

Ballare C, Bravo AI, Sorin I, Guman N, Schiaffi JA, Yomha R, Bagnati A, Lema B, Mordoh J.

Cancer. 1991 Mar 1;67(5):1352-8.

PMID:
1991298
43.

DNA synthesis in estrogen receptor-positive human breast cancer takes place preferentially in estrogen receptor-negative cells.

Ballare C, Bravo AI, Laucella S, Sorin I, Cerdeiro R, Loza J, Sousa Martinez F, Guman N, Mordoh J.

Cancer. 1989 Aug 15;64(4):842-8.

PMID:
2743278
44.

In vitro analysis of the cellular proliferative response to 17-beta-estradiol of human breast cancer.

Podhajcer OL, Bravo AI, Dain L, Guman N, Bover L, Mordoh J.

Cancer. 1988 May 1;61(9):1807-12.

PMID:
3281743
45.

Subpopulations of MCF7 cells separated by Percoll gradient centrifugation: a model to analyze the heterogeneity of human breast cancer.

Resnicoff M, Medrano EE, Podhajcer OL, Bravo AI, Bover L, Mordoh J.

Proc Natl Acad Sci U S A. 1987 Oct;84(20):7295-9.

46.

Determination of DNA synthesis, estrogen receptors, and carcinoembryonic antigen in isolated cellular subpopulations of human breast cancer.

Podhajcer OL, Bravo AI, Sorin I, Guman N, Cerdeiro R, Mordoh J.

Cancer. 1986 Aug 1;58(3):720-9.

PMID:
3524793

Supplemental Content

Loading ...
Support Center